NEW YORK (GenomeWeb) – Citigroup this week initiated coverage of Cepheid with a Buy rating and a price target on its shares of $52.

In a report, Citigroup analyst Daniel Arias highlighted as positives the Sunnyvale, Calif.-based molecular diagnostic firm's RT-PCR technology, which he called "best in class;" its market leadership in infectious diseases, and an installed base of more than 7,000 GeneXpert systems. He added that he anticipates total commercial instrument sales to grow 6 percent in 2014 and 7 percent in 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.